Rallybio Corp's Chief Executive Officer, Stephen Uden, has made a significant move by acquiring 22,456 shares of the company's common stock at a price of $6.08 each. This transaction took place on October 6, 2026, and brings Uden's total ownership to 115,620 shares. This acquisition is a strong indicator of Uden's confidence in Rallybio's future and its potential in the competitive pharmaceutical preparations industry.
Rallybio Corp, incorporated in Delaware, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol RLYB. As an emerging growth company, Rallybio is focused on developing innovative therapies to address unmet medical needs.
According to the recent SEC filing (accession number 0001193125-26-418051), Uden's acquisition was categorized as a direct ownership transaction. The filing states, "transaction code M," indicating that the shares were acquired. Following this transaction, Uden holds a total of 115,620 shares of Rallybio's common stock.
This acquisition may impact various stakeholders, including investors, employees, and competitors in the pharmaceutical industry. Uden's increased stake in the company could signal to investors that he believes in Rallybio's growth trajectory, potentially influencing market perceptions and investor sentiment.
The filing does not say what happens next regarding further transactions or strategic plans following this acquisition.